We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Results: 3

2.
Fig. 2

Fig. 2. From: Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients.

Effect of CEP-1347 on the concentration versus time profile of atazanavir (meanĀ±SEM). Shown are individual atazanavir (300 mg once daily) concentrations in plasma at each time point from visit 1 and 2 in study participants taking CEP-1347 (50 mg twice daily)

Qing Ma, et al. J Neurovirol. 2013 June;19(3):254-260.
3.
Fig. 1

Fig. 1. From: Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients.

Effect of CEP-1347 on the time versus concentration curves of ritonavir (meanĀ±SEM). Shown are individual ritonavir (100 mg once daily) concentrations in plasma at each time point from visit 1 (before) to 2 (after) in study participants taking CEP-1347 (50 mg twice daily)

Qing Ma, et al. J Neurovirol. 2013 June;19(3):254-260.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk